Dabigatran Etexilate
A RAPID STABILITY INDICATING RP-HPLC ASSAY METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTITATIVE ESTIMATION OF DABIGATRAN ETEXILATE MESYLATE IN CAPSULESP.Manasa,P.Sowndarya, K.Mounika,A.Ashok Kumar*DOWNLOAD/VIEW
... Dabigatran etexilate (DE) is the oral prodrug of the active moiety ...The dabigatran etexilate pro-drug was developed due to the limited oral availability of dabigatran, and it is ...
11
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF DABIGATRAN ETEXILATE IN PURE AND DOSAGE FORMS BY USING RP-HPLC METHOD
... Preparation of Sample working solutions (100%): Accurately weigh 20capsules, mix the contents and transfer the pellets equivalent to 290mg of Dabigatran Etexilate into a 250mL volumetric flask. Add 160mL of ...
9
An Improved Process for the Preparation of Dabigatran Etexilate Mesylate and Synthesis of its Impurities
... of dabigatran etexilate mesylate and impurities ...desired Dabigatran Etexilate from the methane sulfonic acid it is finally as a dabigatran etexilate mesylate salt with an ...
22
Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice
... with dabigatran etexilate and (B) age-matched control demonstrating a significant difference in oil-red-O-positive ...with dabigatran etexilate for 20 weeks and (D) age-matched control, ...
9
Development and validation of RP- HPLC method for the estimation of dabigatran etexilate mesylate (DEM) in bulk form
... The RP- HPLC method was developed and validated for the determination of Dabigatran Etexilate Mesylate (DEM) in bulk form. The chromatography was carried out on Unisol C18 (4.6 × 150 mm, 3μm) using a mobile ...
7
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF DABIGATRAN ETEXILATE RELATED SUBSTANCE IN PHARMACEUTICAL DOSAGE FORM BY REVERSE‑PHASE – HIGH‑PERFORMANCE LIQUID CHROMATOGRAPHY
... Dabigatran Etexilate (DE) (BIBR 1048) is a newly approved oral direct thrombin inhibitor which is indicated for anticoagulation therapy to reduce the risk of strokes and systemic embolism in patients with ...
8
Impact of Pharmacists’ audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study
... Dabigatran etexilate methanesulfonate (JAN) is the first direct oral anticoagulant (DOAC) launched in Japan for preventing thromboembolic complications in patients with non-valvular atrial fibrillation ...
8
Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease
... to dabigatran etexilate, and the medication was ...As dabigatran etexilate was a new anticoagulation agent at the time, the hospital did not have a reversal protocol for dabigatran ...
5
Stability-indicating RP-HPLC method for determining related substances in Dabigatran etexilate mesylate drug substance
... Dabigatran etexilate is an oral prodrug that is used by a serum esterase to ...clumps. Dabigatran etexilate might be utilized to diminish the danger of venous thromboembolic occasions in ...
16
New options with dabigatran etexilate in anticoagulant therapy
... drugs. Dabigatran etexilate belongs to a new class of direct thrombin ...administration, dabigatran reaches peak plasma concentrations within 2 hours, shows linear pharmacokinetics, and a limited ...
11
Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting
... of dabigatran etexilate 220 mg once daily in patients undergoing THR or TKR, and in subgroups of patients with potentially increased risk of bleeding or venous thromboembolism ...receive dabigatran ...
10
The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
... Dabigatran etexilate was the first FDA approved version of a novel class of oral anticoagulants known as NOACs. It has become a widely available treatment alternative to dose adjusted warfarin for stroke ...
12
Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
... which dabigatran etexilate is currently at the most advanced stage of development, is the greatest advance in the provision of convenient anticoagulation therapy for many ...treatment, dabigatran ...
5
DABIGATRAN ETEXILATE: NEW DIRECT THROMBIN INHIBITORS ANTICOAGULANTS
... neither dabigatran etexilate nor its active moiety, dabigatran, has been shown to be metabolized by the human CYP system, nor did they exhibit effects on human CYP ...of dabigatran with ...
6
Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials
... Dabigatran etexilate (hereafter referred to as dabigatran) is an orally administered direct, reversible thrombin inhibitor for the prevention and treatment of various thromboembolic ...of ...
9
Development and validation of UV- spectrophotometric method for the estimation of dabigatran etexilate mesylate (dem)
... The literature survey reveals that various analytical methods like Spectrophotometric, HPLC were reported for the determination of DEM in formulations. UV-Spectrophotometric method was developed with acetone as solvent ...
6
QbD Approach Method Development for Estimation of Dabigatran Etexilate along with Its Impurities and Identification of Degradants in Capsule Dosage Form
... Abstract The concept of Quality by Design was demonstrated in the development of a stability-indicating assay and related substances method by HPLC for Dabigatran Etexilate Capsules dosa[r] ...
31
Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
... mg dabigatran etexilate dose was tested as an alternative lower dose for use in certain patient groups with an increased risk of bleeding, such as patients aged over 75 years and those with moderate renal ...
9
A 12 month review of a modified protocol using low dose Dabigatran Etexilate in postoperative thromboembolic prophylaxis in joint replacement surgery
... of Dabigatran (150 mg and 220 mg once-daily) starting postoperatively, with subcutaneous Enoxaparin, in patients undergoing hip (RE-NOVATE [6]) or knee arthroplasty (RE-MOBILIZE [9] and RE-MODEL ...of ...
5
Dabigatran etexilate tetrahydrate
... Data collection: CrystalClear Rigaku/MSC, 2009; cell refinement: CrystalClear; data reduction: CrystalClear; programs used to solve structure: SHELXS97 Sheldrick, 2008; programs used to [r] ...
12